Leprosy Control Program

Pangalan ng Kumpanya: 

Novartis Healthcare Philippines, Inc.

Mga Partners:

  1. World Health Organization (WHO)
  2.  Department of Health (WHO)
  3. Local Government Units (LGUs)
  4. Leprosy advocacy groups
  5. Novartis Foundation for Sustainable Development
Taon na nagsimula ang programa:
2000
Para sa anong kondisyon ito?
Leprosy
Para kanino ang programa?
Patients with Leprosy
Deskripsyon ng programa:
Since 2000 Novartis, through the WHO, has provided at no cost close to
100 percent of the global supply of multidrug therapy (MDT) against
leprosy. This donation, which is equivalent to US$77M, has helped cure
approximately 5 million patients worldwide.
Since 2000, Novartis has supplied at no cost more than 47,000 MDT
courses to the Philippines, accounting for over 60 percent of WHO’s
total MDT supply to the country since 1995.
Recommended by WHO since 1981, MDT has revolutionized the
treatment of leprosy. It consists of 3 drugs: dapsone, rifampicin and
clofazimine. MDT has made it possible to cure patients, interrupt the
transmission of leprosy and prevent disabilities. Even patients with the
severest form of the disease show visible clinical improvement within
weeks of starting treatment. Two of the three drugs used in MDT were
developed in the research laboratories of Novartis.
In October 2010, Novartis and WHO formally announced the extension of
their anti-leprosy collaboration until 2015. Novartis will continue to
provide free MDT medicines. The company’s donation to WHO, valued at
about US$26M, will treat an estimated 1.1 million leprosy patients
worldwide during the five-year commitment. In addition, Novartis will
provide up to US$2.5M to cover costs incurred by WHO for handling the
donation and logistics.

Saan maaaring pumunta?

Municipal or City Health Center

Saan tatawag para sa mga katanungan tungkol sa programa?

Patients can get in touch with their Municipal or City Health Center.